Dutch rare disease biotech ProQR carves out new company dedicated to epidermolysis bullosa
Nine months after kickstarting human testing for its exon skipping drug for a rare skin disorder called dystrophic epidermolysis bullosa, Dutch biotech ProQR Therapeutics is spinning off the program into a new company — Wings Therapeutics — formed and financed by a nonprofit founded by a group of parents, including Pearl Jam’s Eddie Vedder.
The ongoing Phase I/II study is testing the drug — QR-313 — in patients with recessive dystrophic epidermolysis bullosa (DEB), a severe form of an inherited skin blistering disease that is characterized by fragile skin, chronic pain and a high risk of infection and malnutrition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.